Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

News Daily News

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

Michael O'Riordan

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

September 16, 2022

FDA Approves Pascal TEER Device for Degenerative MR

News Daily News

FDA Approves Pascal TEER Device for Degenerative MR

September 15, 2022

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

News Daily News

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

Michael O'Riordan

July 19, 2022

TCTMD’s Top 10 Most Popular Stories for June 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

July 04, 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

News Conference News EuroPCR 2022

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

Michael O'Riordan

May 20, 2022

Modified Surgical MV Repair Stands Up to Replacement

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.